ADMA Biologics Financial Ratios
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ADMA Biologics ratio analysis
ADMA Biologics earned a net margin of 28.8% in FY 2025, down from 46.4% a year earlier. Gross margin was 57.4% compared with a median of 1.4% over the prior 9 years. Return on equity reached 30.8%, meaning ADMA Biologics generated 0.31 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.15 versus 0.21 the year before, and the current ratio was 6.71. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
ADMA Biologics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 29.80 | 22.77 | — | — | — | — | — | — | — | — |
| Price / sales | 8.35 | 10.08 | 3.92 | 4.98 | 2.43 | 3.98 | 6.96 | 7.85 | 3.23 | 5.84 |
| Price / book | 8.93 | 12.31 | 7.49 | 5.05 | 1.39 | 1.90 | 7.80 | 6.74 | 1.82 | — |
| Gross margin | 57.4% | 51.5% | 34.4% | 22.9% | 1.4% | -45.2% | -34.6% | -148.4% | -28.1% | 40.3% |
| Operating margin | 37.5% | 32.6% | 8.4% | -25.5% | -72.1% | -153.8% | -141.1% | -354.9% | -172.7% | -162.6% |
| Net margin | 28.8% | 46.4% | -10.9% | -42.8% | -88.5% | -179.4% | -164.5% | -387.1% | -192.3% | -183.1% |
| Free cash flow margin | 5.5% | 25.9% | 1.6% | -47.6% | -155.5% | -271.7% | -272.6% | -381.4% | -175.5% | -172.1% |
| Return on equity (ROE) | 30.8% | 56.6% | -20.9% | -43.4% | -50.8% | -85.8% | -184.3% | -332.5% | -108.5% | — |
| Return on assets (ROA) | 23.5% | 40.5% | -8.6% | -18.9% | -25.9% | -36.5% | -38.0% | -74.0% | -40.5% | -82.4% |
| Debt / equity | 0.15 | 0.21 | 0.97 | 0.94 | 0.67 | 1.05 | 2.61 | 1.34 | 0.63 | — |
| Current ratio | 6.71 | 5.97 | 5.16 | 6.89 | 6.87 | 7.71 | 6.12 | 4.63 | 6.60 | 1.93 |
| Revenue growth | 19.6% | 65.2% | 67.6% | 90.4% | 91.7% | 43.9% | 72.8% | -25.4% | 113.5% | 48.5% |
| EPS growth | -25.9% | — | — | — | — | — | — | — | — | — |